160 related articles for article (PubMed ID: 37917812)
21. Genomics of
Lipsyc-Sharf M; Jain E; Collins LC; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Come SE; Peppercorn JM; Borges VF; Warner E; Snow C; Krop IE; Kim D; Weiss J; Zanudo JGT; Partridge AH; Wagle N; Waks AG
JCO Precis Oncol; 2023 Jun; 7():e2300076. PubMed ID: 37364233
[TBL] [Abstract][Full Text] [Related]
22. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
23.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
24. Rates of
Gottesdiener LS; O'Connor S; Busam KJ; Won H; Solit DB; Hyman DM; Shoushtari AN
Clin Cancer Res; 2018 Dec; 24(23):5815-5819. PubMed ID: 30093446
[TBL] [Abstract][Full Text] [Related]
25. An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
Yang ZY; Yang L; Xu CW; Wang XJ; Lei L
Biol Open; 2020 Jan; 9(1):. PubMed ID: 31980423
[TBL] [Abstract][Full Text] [Related]
26. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
28. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.
Hirotsu Y; Nakagomi H; Amemiya K; Oyama T; Inoue M; Mochizuki H; Omata M
Med Oncol; 2017 Jan; 34(1):3. PubMed ID: 27900589
[TBL] [Abstract][Full Text] [Related]
29. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene.
Khoury T; Mojica W; Hicks D; Starostik P; Ademuyiwa F; Janarthanan B; Cheney RT
Mod Pathol; 2011 Aug; 24(8):1055-9. PubMed ID: 21499233
[TBL] [Abstract][Full Text] [Related]
30. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.
Roscigno M; Cha EK; Rink M; Seitz C; Novara G; Chromecki TF; Fritsche HM; Matsumoto K; Walton TJ; Carballido J; Filippo Da Pozzo L; Bertini R; Ficarra V; Otto W; Karakiewicz PI; Pycha A; Fajkovic H; Naspro R; Scherr DS; Montorsi F; Shariat SF
BJU Int; 2012 Sep; 110(5):674-81. PubMed ID: 22348322
[TBL] [Abstract][Full Text] [Related]
31. Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
Surette A; Yoo BH; Younis T; Matheson K; Rameh T; Snowdon J; Bethune G; Rosen KV
Breast Cancer Res Treat; 2021 Jun; 187(3):743-758. PubMed ID: 33728523
[TBL] [Abstract][Full Text] [Related]
32. Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
Tsujino T; Takahara K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Hirano H; Nomi H; Ibuki N; Inamoto T; Azuma H
J Med Case Rep; 2017 Apr; 11(1):99. PubMed ID: 28391777
[TBL] [Abstract][Full Text] [Related]
33. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
[TBL] [Abstract][Full Text] [Related]
34. Protein gene product 9.5 is diagnostically helpful in delineating high-grade renal cell cancer involving the renal medullary/sinus region from invasive urothelial cell carcinoma of the renal pelvis.
Gunia S; Erbersdobler A; Koch S; Otto W; Staibano S; D'Alterio C; Brookman-May S
Hum Pathol; 2013 May; 44(5):712-7. PubMed ID: 23158209
[TBL] [Abstract][Full Text] [Related]
35. Association of
Hino K; Nishina T; Kajiwara T; Bando H; Nakamura M; Kadowaki S; Minashi K; Yuki S; Ohta T; Hara H; Mizukami T; Moriwaki T; Ohtsubo K; Komoda M; Mitani S; Nagashima F; Kato K; Yamada T; Hasegawa H; Yamazaki K; Yoshino T; Hyodo I
JCO Precis Oncol; 2022 Aug; 6():e2200135. PubMed ID: 35952320
[TBL] [Abstract][Full Text] [Related]
36. Nephrogenic adenoma of the renal pelvis: A rare case report and review of the literature.
Zhang F; Wu J; Sun Z; Xie D; Yang X; Wang W
Medicine (Baltimore); 2021 Aug; 100(34):e27025. PubMed ID: 34449477
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
Czito B; Zietman A; Kaufman D; Skowronski U; Shipley W
J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822
[TBL] [Abstract][Full Text] [Related]
38. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
[TBL] [Abstract][Full Text] [Related]
39. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract.
Tsai YS; Tzai TS; Chow NH; Wu CL
Urology; 2005 Dec; 66(6):1197-202. PubMed ID: 16360440
[TBL] [Abstract][Full Text] [Related]
40. A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation.
Maurer-Gebhard M; Schmidt M; Azemar M; Stöcklin E; Wels W; Groner B
Hybridoma; 1999 Feb; 18(1):69-75. PubMed ID: 10211791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
